StageZero Life Sciences Ltd. (SZLSF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 8.2 Million USD | 4.06% |
| 2021 | 7.88 Million USD | -19.06% |
| 2020 | 9.74 Million USD | 50.88% |
| 2019 | 6.45 Million USD | -11.83% |
| 2018 | 7.32 Million USD | 28.26% |
| 2017 | 5.7 Million USD | -30.12% |
| 2016 | 8.16 Million USD | 248.5% |
| 2015 | 2.34 Million USD | 202.04% |
| 2014 | 776.12 Thousand USD | -37.93% |
| 2013 | 1.25 Million USD | -74.84% |
| 2012 | 4.96 Million USD | 13.1% |
| 2011 | 4.39 Million USD | -10.48% |
| 2010 | 4.9 Million USD | 26.84% |
| 2009 | 3.86 Million USD | -9.14% |
| 2008 | 4.25 Million USD | -18.45% |
| 2007 | 5.22 Million USD | 216.39% |
| 2006 | 1.65 Million USD | -42.02% |
| 2005 | 2.84 Million USD | -47.82% |
| 2004 | 5.45 Million USD | 914.42% |
| 2003 | 537.81 Thousand USD | 53.92% |
| 2002 | 349.41 Thousand USD | 333.38% |
| 2001 | 80.62 Thousand USD | -87.53% |
| 2000 | 646.52 Thousand USD | 18556.3% |
| 1999 | 3465.44 USD | 21.33% |
| 1998 | 2856.12 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 11.32 Million USD | 7.13% |
| 2024 Q1 | 10.56 Million USD | 0.0% |
| 2023 Q1 | 9.66 Million USD | 17.75% |
| 2023 Q2 | 9.19 Million USD | -4.79% |
| 2023 Q3 | 9.58 Million USD | 4.19% |
| 2022 Q2 | 7.2 Million USD | 11.79% |
| 2022 Q1 | 6.44 Million USD | -18.29% |
| 2022 FY | 8.2 Million USD | 4.06% |
| 2022 Q4 | 8.2 Million USD | 17.86% |
| 2022 Q3 | 6.96 Million USD | -3.34% |
| 2021 FY | 7.88 Million USD | -19.06% |
| 2021 Q4 | 7.88 Million USD | 15.58% |
| 2021 Q3 | 6.82 Million USD | 15.59% |
| 2021 Q2 | 5.9 Million USD | -53.72% |
| 2021 Q1 | 12.75 Million USD | 30.89% |
| 2020 Q4 | 9.74 Million USD | -21.14% |
| 2020 FY | 9.74 Million USD | 50.88% |
| 2020 Q1 | 8.38 Million USD | 29.86% |
| 2020 Q2 | 8.8 Million USD | 5.05% |
| 2020 Q3 | 12.35 Million USD | 40.24% |
| 2019 Q4 | 6.45 Million USD | -24.62% |
| 2019 Q2 | 13.62 Million USD | -2.21% |
| 2019 Q1 | 13.93 Million USD | 90.26% |
| 2019 Q3 | 8.56 Million USD | -37.13% |
| 2019 FY | 6.45 Million USD | -11.83% |
| 2018 Q4 | 7.32 Million USD | -3.44% |
| 2018 FY | 7.32 Million USD | 28.26% |
| 2018 Q1 | 5.52 Million USD | -3.17% |
| 2018 Q2 | 7.82 Million USD | 41.61% |
| 2018 Q3 | 7.58 Million USD | -3.13% |
| 2017 Q4 | 5.7 Million USD | -15.07% |
| 2017 Q3 | 6.72 Million USD | -8.54% |
| 2017 FY | 5.7 Million USD | -30.12% |
| 2017 Q1 | 8.35 Million USD | 2.27% |
| 2017 Q2 | 7.34 Million USD | -12.03% |
| 2016 Q1 | 6.89 Million USD | 194.29% |
| 2016 FY | 8.16 Million USD | 248.5% |
| 2016 Q4 | 8.16 Million USD | -8.16% |
| 2016 Q3 | 8.89 Million USD | 19.62% |
| 2016 Q2 | 7.43 Million USD | 7.79% |
| 2015 FY | 2.34 Million USD | 202.04% |
| 2015 Q4 | 2.34 Million USD | 45.17% |
| 2015 Q1 | 722.55 Thousand USD | -6.9% |
| 2015 Q2 | 1.51 Million USD | 109.58% |
| 2015 Q3 | 1.61 Million USD | 6.63% |
| 2014 Q2 | 2.87 Million USD | 170.26% |
| 2014 FY | 776.12 Thousand USD | -37.93% |
| 2014 Q1 | 1.06 Million USD | -14.91% |
| 2014 Q4 | 776.12 Thousand USD | 43.7% |
| 2014 Q3 | 540.09 Thousand USD | -81.22% |
| 2013 FY | 1.25 Million USD | -74.84% |
| 2013 Q3 | 6.29 Million USD | 20.57% |
| 2013 Q1 | 5.04 Million USD | 1.47% |
| 2013 Q2 | 5.21 Million USD | 3.47% |
| 2013 Q4 | 1.25 Million USD | -80.12% |
| 2012 Q2 | 4.51 Million USD | -0.06% |
| 2012 Q3 | 5.15 Million USD | 14.02% |
| 2012 Q1 | 4.52 Million USD | 2.91% |
| 2012 Q4 | 4.96 Million USD | -3.55% |
| 2012 FY | 4.96 Million USD | 13.1% |
| 2011 FY | 4.39 Million USD | -10.48% |
| 2011 Q4 | 4.39 Million USD | 6.55% |
| 2011 Q1 | 5.3 Million USD | 8.12% |
| 2011 Q2 | 4.33 Million USD | -18.36% |
| 2011 Q3 | 4.12 Million USD | -4.81% |
| 2010 Q4 | 4.9 Million USD | 16.89% |
| 2010 FY | 4.9 Million USD | 26.84% |
| 2010 Q1 | 3.96 Million USD | 2.43% |
| 2010 Q2 | 3.72 Million USD | -5.89% |
| 2010 Q3 | 4.19 Million USD | 12.57% |
| 2009 Q2 | 3.89 Million USD | -15.85% |
| 2009 Q3 | 4.26 Million USD | 9.45% |
| 2009 FY | 3.86 Million USD | -9.14% |
| 2009 Q1 | 4.62 Million USD | 8.69% |
| 2009 Q4 | 3.86 Million USD | -9.24% |
| 2008 Q4 | 4.25 Million USD | 9.98% |
| 2008 FY | 4.25 Million USD | -18.45% |
| 2008 Q1 | 4.36 Million USD | -16.34% |
| 2008 Q2 | 4.2 Million USD | -3.66% |
| 2008 Q3 | 3.87 Million USD | -7.99% |
| 2007 Q3 | 2.51 Million USD | 36.17% |
| 2007 Q4 | 5.22 Million USD | 107.31% |
| 2007 FY | 5.22 Million USD | 216.39% |
| 2007 Q1 | 1.63 Million USD | -1.03% |
| 2007 Q2 | 1.84 Million USD | 13.24% |
| 2006 FY | 1.65 Million USD | -42.02% |
| 2006 Q1 | 2.69 Million USD | -5.16% |
| 2006 Q2 | 1.9 Million USD | -29.57% |
| 2006 Q3 | 1.38 Million USD | -27.33% |
| 2006 Q4 | 1.65 Million USD | 19.45% |
| 2005 Q2 | 3.71 Million USD | -11.05% |
| 2005 Q3 | 3.56 Million USD | -4.1% |
| 2005 Q4 | 2.84 Million USD | -20.05% |
| 2005 FY | 2.84 Million USD | -47.82% |
| 2005 Q1 | 4.17 Million USD | -23.49% |
| 2004 Q1 | 619.47 Thousand USD | 15.18% |
| 2004 Q3 | 1.24 Million USD | 87.75% |
| 2004 Q4 | 5.45 Million USD | 336.65% |
| 2004 FY | 5.45 Million USD | 914.42% |
| 2004 Q2 | 665.49 Thousand USD | 7.43% |
| 2003 FY | 537.81 Thousand USD | 53.92% |
| 2003 Q4 | 537.81 Thousand USD | 88.86% |
| 2003 Q3 | 284.77 Thousand USD | -8.62% |
| 2003 Q2 | 311.64 Thousand USD | -2.29% |
| 2003 Q1 | 318.93 Thousand USD | -23.61% |
| 2002 Q1 | 211.2 Thousand USD | 29.29% |
| 2002 Q3 | 183.19 Thousand USD | 14.37% |
| 2002 Q4 | 417.52 Thousand USD | 127.92% |
| 2002 FY | 349.41 Thousand USD | 333.38% |
| 2002 Q2 | 160.17 Thousand USD | -24.16% |
| 2001 Q3 | 70.92 Thousand USD | -12.03% |
| 2001 Q4 | 163.35 Thousand USD | 130.32% |
| 2001 Q1 | 139.94 Thousand USD | -44.18% |
| 2001 FY | 80.62 Thousand USD | -87.53% |
| 2001 Q2 | 80.62 Thousand USD | -42.38% |
| 2000 Q3 | 56.81 Thousand USD | 0.0% |
| 2000 FY | 646.52 Thousand USD | 18556.3% |
| 2000 Q1 | 4204.51 USD | 21.33% |
| 2000 Q4 | 250.71 Thousand USD | 341.28% |
| 1999 Q1 | 1721.58 USD | 0.0% |
| 1999 FY | 3465.44 USD | 21.33% |
| 1999 Q2 | 4828.79 USD | 180.49% |
| 1999 Q3 | 5004.18 USD | 3.63% |
| 1999 Q4 | 3465.44 USD | -30.75% |
| 1998 FY | 2856.12 USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -127.383% |
| Arrayit Corporation | 7.49 Million USD | -9.436% |
| Atlantic International Corp. | 3.82 Million USD | -114.281% |
| Biocept, Inc. | 22.01 Million USD | 62.731% |
| Bioqual, Inc. | 18.93 Million USD | 56.68% |
| CardioGenics Holdings Inc | 1.79 Million USD | -357.066% |
| DermTech, Inc. | 64.75 Million USD | 87.331% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 98.884% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | 33.764% |
| iMD Companies, Inc. | 1.67 Million USD | -390.02% |
| IDenta Corp. | 1.01 Million USD | -709.744% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 70.863% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -2653.506% |
| InVitro International | 78.99 Thousand USD | -10286.111% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | 58.417% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -6245.073% |
| Medical Imaging Corp. | 9.51 Million USD | 13.797% |
| NovelStem International Corp. | 4.2 Million USD | -95.051% |
| Optigenex Inc. | 9.57 Million USD | 14.279% |
| PharmChem, Inc. | 558.64 Thousand USD | -1368.546% |
| Proteome Sciences plc | 18.48 Million USD | 55.628% |
| Response Genetics, Inc | 15.86 Million USD | 48.295% |
| Rennova Health, Inc. | 49.66 Million USD | 83.482% |
| RushNet, Inc. | 6.23 Million USD | -31.495% |
| ScreenPro Security Inc. | 1.6 Million USD | -412.561% |
| Stella Diagnostics Inc. | 18 Million USD | 54.436% |
| Todos Medical Ltd. | 50.15 Million USD | 83.643% |